Literature DB >> 22550280

Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification.

Anca M Avram1.   

Abstract

Staging and risk stratification predicate the postoperative management of thyroid cancer patients, determining not only the need for (131)I therapy or alternative options (conservative management without ablation, surgical reintervention, or external-beam radiation therapy) but also the long-term follow-up strategy. This paper presents the progress made in the field of thyroid cancer imaging by application of SPECT/CT technology to radioiodine scintigraphy in both diagnostic and post-therapy settings and reviews the impact of fusion radioiodine imaging on staging, risk stratification, and clinical management of patients with thyroid cancer. In addition, this paper addresses the role of preablation radioiodine imaging and provides nuclear medicine physicians with the background knowledge required for integrating information from fusion imaging into the clinical and histopathologic risk stratification for developing an individualized treatment plan for patients with thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550280     DOI: 10.2967/jnumed.111.104133

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.

Authors:  W Xia; D Li; G Wang; J Ni; J Zhuang; M Ha; J Wang; Y Ye
Journal:  Cancer Gene Ther       Date:  2016-09-09       Impact factor: 5.987

2.  RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.

Authors:  Rebecca Zeuren; Agnese Biagini; Ravinder K Grewal; Gregory W Randolph; Dipti Kamani; Mona M Sabra; Ashok R Shaha; R Michael Tuttle
Journal:  Laryngoscope       Date:  2015-04-17       Impact factor: 3.325

3.  Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy.

Authors:  Valentina Zilioli; Alessia Peli; Maria Beatrice Panarotto; Giancarlo Magri; Ahmed Alkraisheh; Christiane Wiefels; Carlo Rodella; Raffaele Giubbini
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

4.  American Thyroid Association statement on preoperative imaging for thyroid cancer surgery.

Authors:  Michael W Yeh; Andrew J Bauer; Victor A Bernet; Robert L Ferris; Laurie A Loevner; Susan J Mandel; Lisa A Orloff; Gregory W Randolph; David L Steward
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

Review 5.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

6.  ¹²⁴I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy ¹³¹I SPECT/CT.

Authors:  Cecile de Pont; Servais Halders; Jan Bucerius; Felix Mottaghy; Boudewijn Brans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

Review 7.  SPECT/CT in the Treatment of Differentiated Thyroid Cancer.

Authors:  Sang-Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-02-08

8.  Nuclear Medicine in Thyroid Diseases in Pediatric and Adolescent Patients.

Authors:  Bilge Volkan-Salancı; Pınar Özgen Kıratlı
Journal:  Mol Imaging Radionucl Ther       Date:  2015-06-05

9.  SPECT/CT localization of oral radioiodine activity: a retrospective study and in-vitro assessment.

Authors:  Jared S Burlison; Michael F Hartshorne; Alan M Voda; Franklin H Cocks; Joanna R Fair
Journal:  Nucl Med Commun       Date:  2013-12       Impact factor: 1.690

10.  Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer.

Authors:  Shozo Okamoto; Tohru Shiga; Yuko Uchiyama; Osamu Manabe; Kentaro Kobayashi; Keiichiro Yoshinaga; Nagara Tamaki
Journal:  Ann Nucl Med       Date:  2013-12-28       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.